Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters.
Christine PhoMadison FrielerGiri R AkkarajuAnton V NaumovHana M DobrovolnyPublished in: In silico pharmacology (2021)
One of the primary cancer treatment modalities is chemotherapy. Unfortunately, traditional anti-cancer drugs are often not selective and cause damage to healthy cells, leading to serious side effects for patients. For this reason more targeted therapeutics and drug delivery methods are being developed. The effectiveness of new treatments is initially determined via in vitro cell viability assays, which determine the IC 50 of the drug. However, these assays are known to result in estimates of IC 50 that depend on the measurement time, possibly resulting in over- or under-estimation of the IC 50 . Here, we test the possibility of using cell growth curves and fitting of mathematical models to determine the IC 50 as well as the maximum efficacy of a drug ( ε max ). We measured cell growth of MCF-7 and HeLa cells in the presence of different concentrations of doxorubicin and fit the data with a logistic growth model that incorporates the effect of the drug. This method leads to measurement time-independent estimates of IC 50 and ε max , but we find that ε max is not identifiable. Further refinement of this methodology is needed to produce uniquely identifiable parameter estimates.
Keyphrases
- drug delivery
- induced apoptosis
- cell cycle arrest
- cancer therapy
- end stage renal disease
- ejection fraction
- oxidative stress
- randomized controlled trial
- high throughput
- newly diagnosed
- chronic kidney disease
- endoplasmic reticulum stress
- systematic review
- locally advanced
- drug induced
- signaling pathway
- pi k akt
- small molecule
- papillary thyroid
- young adults
- machine learning
- patient reported outcomes
- data analysis
- patient reported
- single cell
- chemotherapy induced